Ocata Therapeutics Company Profile (NASDAQ:OCAT)

Analyst Ratings

Consensus Ratings for Ocata Therapeutics (NASDAQ:OCAT) (?)
Ratings Breakdown: 2 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.25 (2.60% downside)

Analysts' Ratings History for Ocata Therapeutics (NASDAQ:OCAT)
Show:
DateFirmActionRatingPrice TargetActions
2/23/2016Cantor FitzgeraldReiterated RatingHold$8.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Raymond James Financial Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2015Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Maxim GroupReiterated RatingBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Ocata Therapeutics (NASDAQ:OCAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/9/2015Q315($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocata Therapeutics (NASDAQ:OCAT)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocata Therapeutics (NASDAQ:OCAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/10/2015Robert LanzainsiderSell35,000$8.31$290,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocata Therapeutics (NASDAQ:OCAT)
DateHeadline
07/26/16 05:54 PMResearch report explores the global age related macular degeneration market consumption forecast to 2021 covering ... - WhaTech
07/21/16 05:54 PMJapan is Breathing Life into the Stem Cell Space, Astellas Pharma NPV (OTCMKTS:ALPMF) & Pluristem Therapeutics ... - Market Exclusive
07/18/16 05:44 PMOcata Therapeutics, Inc. (NASDAQ:OCAT) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 10:29 AMCrowd Rating and Earnings Recap for Ocata Therapeutics, Inc. (NASDAQ:OCAT) - Telanagana Press
07/14/16 09:10 AMOcata Therapeutics, Inc. (NASDAQ:OCAT) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 05:57 PMTrading Performance and Target Watch for Ocata Therapeutics, Inc. (NASDAQ:OCAT) - Press Telegraph
07/08/16 02:05 PMWall Street Ratings and Target Price Views on Ocata Therapeutics, Inc. (NASDAQ:OCAT) - Telanagana Press
07/07/16 08:32 AMOcata Therapeutics, Inc. (NASDAQ:OCAT) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/01/16 08:23 AMSell-Side Recommendation & Price Target Projections on Ocata Therapeutics, Inc. (NASDAQ:OCAT) - Telanagana Press
07/01/16 08:23 AMRecently Issued Stock Ratings For Ocata Therapeutics, Inc. (OCAT) - Fiscal Standard
06/30/16 08:28 AMOcata Therapeutics, Inc. (NASDAQ:OCAT) Company Rating and Target Watch - Telanagana Press
06/28/16 10:27 AMOcata Therapeutics, Inc. (NASDAQ:OCAT) Earnings Glance and Target Price Review - Engelwood Daily
06/21/16 09:59 AMKeryx Biopharmaceuticals Appoints Two New Board Members - PharmiWeb.com (press release)
06/09/16 08:32 AMCynata Appoints Paul K Wotton Ph.D. to Board of Directors - irasia.com (press release)
06/03/16 08:28 AMCantor Fitzgerald Initiates a Buy Rating on Glaukos - Markets.co - Cantor Fitzgerald Initiates a Buy Rating on GlaukosMarkets.coIn comparison, last year the company earned revenue of $14.67M and had a net profit of -$966k. Like Cantor Fitzgerald`s latest rating, based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock ...and more »
06/01/16 08:29 AMStock Review and Earnings Check on Ocata Therapeutics, Inc. (NASDAQ:OCAT) - HNN - Stock Review and Earnings Check on Ocata Therapeutics, Inc. (NASDAQ:OCAT)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Ocata Therapeutics, Inc.and more »
02/07/16 01:45 PMOcata Therapeutics, Inc. (OCAT) Recent Analyst Updates - Risers & Fallers - Ocata Therapeutics, Inc. (OCAT) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Ocata Therapeutics, Inc. (OCAT). According to the latest broker reports outstanding on Friday 5th February, 0 analysts have a rating of “strong buy”, 1 analysts “buy ...
02/07/16 01:45 PMOcata Therapeutics Inc (OCAT) Profit Expected to Increase - OctaFinance.com - Ocata Therapeutics Inc (OCAT) Profit Expected to IncreaseOctaFinance.comAnalysts await Ocata Therapeutics Inc (NASDAQ:OCAT) to reports earnings on February, 8. After $-0.18 actual earnings per share reported by Ocata Therapeutics Inc for the previous quarter, Wall Street now forecasts -33.33 % EPS growth. The stock ...
01/28/16 01:32 PMRecent Broker Updates On Ocata Therapeutics, Inc. (OCAT) - Risers & Fallers - Recent Broker Updates On Ocata Therapeutics, Inc. (OCAT)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Ocata Therapeutics, Inc. (OCAT). The latest broker reports which are currently outstanding on Thursday 28th January state 0 analysts have a rating of “strong buy”, 1 ...
01/27/16 01:00 PMWill Ocata Therapeutics, Inc. (NASDAQ:OCAT) Surprise Analysts This Quarter? - Stocks Daily - Will Ocata Therapeutics, Inc. (NASDAQ:OCAT) Surprise Analysts This Quarter?Stocks DailyOcata Therapeutics, Inc. (NASDAQ:OCAT) posted earnings of $-0.18 per share for the last fiscal quarter which ended on 2015-09-30. The reported number was $0.01 away from the Zacks consensus estimate which was calculated just prior to the earnings ...Ocata Therapeutics, Inc. (NASDAQ:OCAT): Analysts Take on EarningsSmallCapWired.comall 5 news articles »
01/26/16 01:31 PMOcata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate - Seeking Alpha - Ocata Shareholder Majority Rejects Astellas Offer As Woefully InadequateSeeking AlphaOcata Therapeutics majority shareholders (NASDAQ: OCAT) have again, after this third offer, indicated that its Board of Directors has erred in its unanimous recommendation for the solicited tender offer by Astellas to acquire all of the outstanding ...Hot Biotech Stocks To Watch Right Now: Sarepta Therapeutics, Inc. (SRPT), Ocata Therapeutics, Inc. (OCAT), Dyax ...iStreetWireall 3 news articles »
01/25/16 12:48 PMHot Biotech Stocks To Watch Right Now: Sarepta Therapeutics, Inc. (SRPT), Ocata Therapeutics, Inc. (OCAT), Dyax ... - iStreetWire - Hot Biotech Stocks To Watch Right Now: Sarepta Therapeutics, Inc. (SRPT), Ocata Therapeutics, Inc. (OCAT), Dyax ...iStreetWireSarepta Therapeutics, Inc. (SRPT) closed at $12.11 with a rise of 1.17%. Sarepta Therapeutics, Inc. (SRPT) announced that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Advisory Committee meeting scheduled for ...
01/22/16 12:31 PMAstellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - FierceBiotech - Seeking AlphaAstellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata TherapeuticsFierceBiotechTOKYO and Massachusetts, Jan. 22, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata") today announced that ...Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails AgainSeeking AlphaAstellas Again Extends Tender Offer for Ocata TherapeuticsGenetic Engineering & Biotechnology Newsall 6 news articles »
01/21/16 12:44 PMSmall investors oppose Ocata sale; $379M offer deemed too low for drug 'worth ... - Worcester Telegram - Small investors oppose Ocata sale; $379M offer deemed too low for drug 'worth ...Worcester TelegramMARLBORO – A Japanese company's offer to buy Ocata Therapeutics Inc. is nearing a crucial deadline this week as some of the drug developer's small investors continue to hope the $379 million deal will fall through. Astellas Pharma Inc. of Tokyo is ...
01/20/16 10:25 AMOcata Therapeutics, Inc. – Value Analysis (NASDAQ:OCAT) : January 20, 2016 -

Social

About Ocata Therapeutics

Ocata Therapeutics logoOcata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCAT
  • CUSIP:
Key Metrics:
  • Previous Close: $8.47
  • 50 Day Moving Average: $8.42
  • 200 Day Moving Average: $6.15
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-0.60 EPS
  • Next Year EPS Consensus Estimate: $-0.49 EPS
Additional Links:
Ocata Therapeutics (NASDAQ:OCAT) Chart for Wednesday, July, 27, 2016